Flag of the European Union EU Clinical Trials Register Help

Clinical trials for McDonald criteria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    274 result(s) found for: McDonald criteria. Displaying page 8 of 14.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2007-005450-23 Sponsor Protocol Number: MS-LAQ-302 Start Date*: 2008-03-17
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad...
    Medical condition: Esclerosis Múltiple Remitente Recurrente (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) CZ (Completed) IT (Completed) SK (Completed) LT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000028-36 Sponsor Protocol Number: P3-IMU-838-RMS-01 Start Date*: 2022-04-21
    Sponsor Name:Immunic AG
    Full Title: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) BG (Trial now transitioned) GR (Completed) DE (Trial now transitioned) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002037-20 Sponsor Protocol Number: GA/9016 Start Date*: 2006-07-27
    Sponsor Name:Teva Pharmaceutical Industries, Ltd.
    Full Title: A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetat...
    Medical condition: Relapsing-remitting Multiple Sclerosis (RR MS)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) BE (Completed) GB (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000637-41 Sponsor Protocol Number: EFC16033 Start Date*: 2020-07-31
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) CZ (Completed) FI (Completed) SE (Completed) AT (Completed) DK (Completed) LT (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004847-61 Sponsor Protocol Number: 008717QM Start Date*: 2013-01-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhan...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002683-24 Sponsor Protocol Number: CP-NU100-01.00 Start Date*: 2012-01-30
    Sponsor Name:Nuron Biotech, Inc.
    Full Title: A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis
    Medical condition: Relapsing forms of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000256-26 Sponsor Protocol Number: Start Date*: 2009-02-16
    Sponsor Name:Queen Mary, University of London
    Full Title: An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonβ-1a (IFNβ-1a, Rebif®) therapy in the induction of tolerance to IFNβ in MS patients with neu...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009503-19 Sponsor Protocol Number: TYS-IMA-08-11 Start Date*: 2010-07-20
    Sponsor Name:Biogen Idec International GmbH
    Full Title: A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000395-26 Sponsor Protocol Number: GER-BGT-13-10586 Start Date*: 2015-08-07
    Sponsor Name:Biogen GmbH
    Full Title: A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023021-38 Sponsor Protocol Number: STRIX-MS001 Start Date*: 2011-02-23
    Sponsor Name:Västerbottens läns landsting
    Full Title: Switch To RItuXimab in MS A phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach
    Medical condition: Relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (DMDs), eg beta-interferons or glatiramere acetate
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003145-99 Sponsor Protocol Number: CCMROne Start Date*: 2015-03-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis alread...
    Medical condition: Relapsing-remitting multiple sclerosis already on interferon-beta therapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005586-39 Sponsor Protocol Number: 101MS409 Start Date*: 2015-01-29
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS)
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004701-11 Sponsor Protocol Number: MS200527_0073 Start Date*: 2020-01-10
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsin...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003098-42 Sponsor Protocol Number: 108MS303 Start Date*: 2009-01-06
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis
    Medical condition: To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-002838-23 Sponsor Protocol Number: CL02-ORY-2001MS Start Date*: 2017-10-27
    Sponsor Name:Oryzon Genomics S. A
    Full Title: Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS)...
    Medical condition: patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2023-000018-16 Sponsor Protocol Number: OZA22/IM047-048 Start Date*: 2023-04-19
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study
    Medical condition: Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001224-22 Sponsor Protocol Number: 215MS202 Start Date*: 2017-12-28
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as ...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012716-40 Sponsor Protocol Number: CO-200-201 Start Date*: 2009-12-31
    Sponsor Name:Peptimmune Inc.
    Full Title: The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel,...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) CZ (Completed) DE (Completed) FR (Ongoing) PL (Prematurely Ended) SK (Completed) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014339-19 Sponsor Protocol Number: ONO-4641POU006 Start Date*: 2010-03-26
    Sponsor Name:ONO Pharmaceutical Co., Ltd.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000922-12 Sponsor Protocol Number: TV44400-CNS-40083 Start Date*: 2016-01-04
    Sponsor Name:Teva Pharmaceutical Industries, Ltd
    Full Title: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) IE (Completed) PL (Completed) FI (Completed) ES (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 23:58:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA